AZ buys Ionis’ NASH candidate
AstraZeneca has bought rights to an experimental antisense therapy from Ionis Pharmaceuticals, in a deal that could be worth more than $300 million.
The move, which builds on an existing strategic partnership between the firms, was triggered by the drug’s advance into development, Ionis said.
IONIS-AZ6-2.5-LRx/AZD2693 is designed to inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis (NASH), a progressive form of non-alcoholic fatty liver disease.
AZ will pay a $30 million license fee to Ionis, and takes over responsibility for further development and commercialization of the drug.
Read more: http://www.pharmatimes.com/news/az_buys_ionis_nash_candidate_1231077
The move, which builds on an existing strategic partnership between the firms, was triggered by the drug’s advance into development, Ionis said.
IONIS-AZ6-2.5-LRx/AZD2693 is designed to inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis (NASH), a progressive form of non-alcoholic fatty liver disease.
AZ will pay a $30 million license fee to Ionis, and takes over responsibility for further development and commercialization of the drug.
Read more: http://www.pharmatimes.com/news/az_buys_ionis_nash_candidate_1231077